These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32356711)

  • 1. [Current antiplatelet agents, new inhibitors and therapeutic targets].
    El Alaoui MZ; Guy A; Khalki L; Limami Y; Benomar A; Zaid N; Cherrah Y; Mekhfi H; Cadi R; Zaid Y
    Med Sci (Paris); 2020 Apr; 36(4):348-357. PubMed ID: 32356711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple antiplatelet therapy in acute coronary syndromes.
    Valgimigli M; Minarelli M
    Drugs; 2011 Sep; 71(13):1703-19. PubMed ID: 21902293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
    Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
    McFadyen JD; Schaff M; Peter K
    Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
    Schafer AI
    Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antiplatelet agents in sepsis: a glimpse into the future.
    Akinosoglou K; Alexopoulos D
    Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet drugs: which targets for which treatments?
    Gachet C
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S313-22. PubMed ID: 26149041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiology patient page. Antiplatelet therapy.
    Harrington RA; Hodgson PK; Larsen RL
    Circulation; 2003 Aug; 108(7):e45-7. PubMed ID: 12925447
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Mousa SA
    Curr Pharm Des; 2003; 9(28):2317-22. PubMed ID: 14529393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
    J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific and therapeutic advances in antiplatelet therapy.
    Bhatt DL; Topol EJ
    Nat Rev Drug Discov; 2003 Jan; 2(1):15-28. PubMed ID: 12509756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.
    Ferguson JJ; Zaqqa M
    Drugs; 1999 Dec; 58(6):965-82. PubMed ID: 10651385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
    Ferguson JJ; Waly HM; Wilson JM
    Am Heart J; 1998 Apr; 135(4):S35-42. PubMed ID: 9539494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
    Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
    Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.